med.uni-muenchen.de.2Cannabinoid Research and Treatment Group, Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nußbaumstr. 7, 80336, Munich, Germany.3APOPO, University of Agriculture, Martin-Luther-University, Morogoro, Tanzania.4Vitos Hospital Psychiatry and Psychotherapy, Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-University, Halle-Wittenberg, Germany.Abstract

We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006-August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, attention-deficit hyperactivity disorder, and Tourette

View the Original article

Partage le savoir
error: Content is protected !!